A detailed history of Voya Investment Management LLC transactions in Cor Medix Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 711,949 shares of CRMD stock, worth $7.83 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
711,949
Previous 19,260 3596.52%
Holding current value
$7.83 Million
Previous $83,000 6830.12%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.64 - $8.23 $2.52 Million - $5.7 Million
692,689 Added 3596.52%
711,949 $5.75 Million
Q2 2024

Aug 14, 2024

SELL
$4.08 - $6.39 $285 - $447
-70 Reduced 0.36%
19,260 $83,000
Q1 2024

May 15, 2024

SELL
$2.94 - $4.24 $11,033 - $15,912
-3,753 Reduced 16.26%
19,330 $81,000
Q4 2023

Feb 14, 2024

BUY
$3.0 - $4.01 $3,177 - $4,246
1,059 Added 4.81%
23,083 $86,000
Q3 2023

Nov 14, 2023

BUY
$3.6 - $4.46 $13,316 - $16,497
3,699 Added 20.19%
22,024 $81,000
Q2 2023

Aug 14, 2023

BUY
$3.94 - $5.8 $72,200 - $106,285
18,325 New
18,325 $72,000
Q2 2022

Aug 15, 2022

SELL
$2.73 - $5.61 $41,951 - $86,208
-15,367 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$4.47 - $5.56 $1,394 - $1,734
-312 Reduced 1.99%
15,367 $70,000
Q2 2021

Aug 16, 2021

BUY
$6.05 - $10.09 $9,123 - $15,215
1,508 Added 10.64%
15,679 $108,000
Q1 2021

May 17, 2021

BUY
$6.84 - $17.58 $7,250 - $18,634
1,060 Added 8.08%
14,171 $142,000
Q4 2020

Feb 16, 2021

BUY
$5.0 - $9.15 $15,390 - $28,163
3,078 Added 30.68%
13,111 $97,000
Q2 2020

Aug 14, 2020

SELL
$3.08 - $6.56 $9,064 - $19,306
-2,943 Reduced 22.68%
10,033 $63,000
Q4 2019

Feb 14, 2020

BUY
$4.96 - $7.75 $64,360 - $100,564
12,976 New
12,976 $94,000

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $453M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.